The Coming Psychedelic Boom
Warning to all investors: There's a coming boom that might make the CBD craze look like an outdated investment.
Learn More About The Coming Psychedelic Boom Now!

NAVB Insider Trading (Navidea Biopharmaceuticals)

Insider Ownership Percentage: 0.49%
Insider Buying (Last 12 Months): $156,005.00
Insider Selling (Last 12 Months): $0.00

Navidea Biopharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Navidea Biopharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Navidea Biopharmaceuticals Share Price & Price History

Current Price: $1.70
Price Change: Price Decrease of -0.02 (-1.16%)
As of 07/28/2021 04:59 PM ET

This chart shows the closing price history over time for NAVB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
America Needs This Company
This stock might just be one of America's No.1 tech investments this year.
Read more.

Navidea Biopharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/26/2021Malcolm G. WitterDirectorBuy15,000$1.70$25,500.0078,257View SEC Filing Icon  
4/23/2021Malcolm G WitterDirectorBuy10,000$1.60$16,000.0057,000View SEC Filing Icon  
3/29/2021Malcolm G WitterDirectorBuy21,500$2.07$44,505.0047,000View SEC Filing Icon  
3/3/2021Malcolm G WitterDirectorBuy15,000$2.31$34,650.00
12/28/2020Malcolm G WitterDirectorBuy5,000$2.07$10,350.0010,500View SEC Filing Icon  
8/30/2020John K Jr. ScottMajor ShareholderBuy5,000$5.00$25,000.008,047,162View SEC Filing Icon  
2/20/2020Jed LatkinCEOBuy5,000$1.12$5,600.00
2/13/2020John K Jr. ScottMajor ShareholderBuy2,373,529$0.85$2,017,499.658,042,162View SEC Filing Icon  
6/18/2019John K Jr. ScottMajor ShareholderBuy4,000,000$0.75$3,000,000.005,113,078View SEC Filing Icon  
6/5/2019Jed LatkinCEOBuy1,000$1.26$1,260.0012,950View SEC Filing Icon  
5/17/2019Jed LatkinCEOBuy1,000$1.46$1,460.0010,950View SEC Filing Icon  
5/17/2019Sarah Kathryn RouanDirectorBuy3,350$1.46$4,891.008,350View SEC Filing Icon  
5/15/2019Jed LatkinCEOBuy1,000$1.45$1,450.006,450View SEC Filing Icon  
5/13/2019Claudine BruckDirectorBuy2,550$1.90$4,845.007,550View SEC Filing Icon  
5/13/2019Jed LatkinCEOBuy2,400$1.91$4,584.006,450View SEC Filing Icon  
3/22/2019John K Jr. ScottMajor ShareholderBuy357,143$0.14$50,000.0222,261,565View SEC Filing Icon  
See Full Table
Insider Trading at Navidea Biopharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Navidea Biopharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

6.45% of Navidea Biopharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NAVB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Navidea Biopharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/19/2021Squarepoint Ops LLC28,836$58K0.0%N/A0.099%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley18,883$38K0.0%+84.2%0.065%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC131,618$0.27M0.0%+136.3%0.461%Search for SEC Filing on Google Icon
5/10/2021HighTower Advisors LLC15,465$33K0.0%-57.1%0.054%Search for SEC Filing on Google Icon
5/6/2021Allred Capital Management LLC64,003$0.13M0.1%+20.9%0.224%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC55,695$0.12M0.0%-42.1%0.209%Search for SEC Filing on Google Icon
2/10/2021HighTower Advisors LLC36,065$79K0.0%+14.1%0.135%Search for SEC Filing on Google Icon
1/21/2021Allred Capital Management LLC52,926$0.11M0.1%-19.0%0.198%Search for SEC Filing on Google Icon
8/31/2020Bridgeway Capital Management Inc.62,540$0.25M0.0%N/A0.242%Search for SEC Filing on Google Icon
8/10/2020HighTower Advisors LLC27,540$0.11M0.0%+82.5%0.108%Search for SEC Filing on Google Icon
8/7/2020Virtu Financial LLC17,586$69K0.0%N/A0.069%Search for SEC Filing on Google Icon
7/16/2020OTA Financial Group L.P.65,600$0.26M0.3%N/A0.279%Search for SEC Filing on Google Icon
7/10/2020FNY Investment Advisers LLC105,000$0.41M0.2%-47.4%0.446%Search for SEC Filing on Google Icon
1/13/2020Allred Capital Management LLC24,128$30K0.0%+113.2%0.133%Search for SEC Filing on Google Icon
8/14/2019Vanguard Group Inc.179,985$0.11M0.0%-95.5%1.789%Search for SEC Filing on Google Icon
8/13/2019BlackRock Inc.125,309$79K0.0%-95.0%1.246%Search for SEC Filing on Google Icon
4/12/2019Virtu Financial LLC186,972$26K0.0%+94.1%0.093%Search for SEC Filing on Google Icon
1/29/2018Sowell Financial Services LLC506,634$0.19M0.0%-26.4%0.312%Search for SEC Filing on Google Icon
11/7/2017Sowell Financial Services LLC688,471$0.30M0.1%-54.3%0.424%Search for SEC Filing on Google Icon
8/14/2017Goldman Sachs Group Inc.298,595$0.15M0.0%-13.8%0.185%Search for SEC Filing on Google Icon
8/11/2017Virtu KCG Holdings LLC336,414$0.17M0.0%+305.6%0.208%Search for SEC Filing on Google Icon
8/11/2017California Public Employees Retirement System367,700$0.19M0.0%No Change0.227%Search for SEC Filing on Google Icon
8/11/2017Vanguard Group Inc.4,887,743$2.49M0.0%+1.7%3.023%Search for SEC Filing on Google Icon
8/2/2017Harel Insurance Investments & Financial Services Ltd.780,000$0.40M0.0%No Change0.482%Search for SEC Filing on Google Icon
7/27/2017Spark Investment Management LLC353,400$0.18M0.0%-28.5%0.219%Search for SEC Filing on Google Icon
5/31/2017Sowell Financial Services LLC1,551,874$0.71M0.2%-1.7%0.960%Search for SEC Filing on Google Icon
5/18/2017Goldman Sachs Group Inc.346,311$0.20M0.0%-57.6%0.216%Search for SEC Filing on Google Icon
5/16/2017HighTower Advisors LLC177,966$0.10M0.0%+7.2%0.111%Search for SEC Filing on Google Icon
5/11/2017California Public Employees Retirement System367,700$0.21M0.0%No Change0.236%Search for SEC Filing on Google Icon
5/11/2017Spark Investment Management LLC494,000$0.28M0.0%+17.6%0.318%Search for SEC Filing on Google Icon
2/27/2017Sowell Financial Services LLC1,578,519$0.67M0.2%N/A1.015%Search for SEC Filing on Google Icon
2/6/2017Harel Insurance Investments & Financial Services Ltd.1,120,000$0.72M0.1%+9.8%0.720%Search for SEC Filing on Google Icon
5/13/2016Geode Capital Management LLC825,766$0.78M0.0%+1.2%0.550%Search for SEC Filing on Google Icon
5/13/2016Goldman Sachs Group Inc.3,609,934$3.41M0.0%-7.4%2.403%Search for SEC Filing on Google Icon
5/13/2016Financial Advisory Group10,000$0.36M0.2%No Change0.007%Search for SEC Filing on Google Icon
5/12/2016UBS Group AG2,199,033$2.08M0.0%-7.0%1.464%Search for SEC Filing on Google Icon
5/12/2016State Street Corp2,086,876$1.97M0.0%-0.5%1.389%Search for SEC Filing on Google Icon
5/10/2016BlackRock Institutional Trust Company N.A.2,329,054$2.20M0.0%-1.4%1.551%Search for SEC Filing on Google Icon
5/10/2016BlackRock Fund Advisors3,820,282$3.61M0.0%-5.2%2.543%Search for SEC Filing on Google Icon
5/6/2016TIAA CREF Investment Management LLC494,641$0.47M0.0%No Change0.329%Search for SEC Filing on Google Icon
2/5/2016Commerzbank Aktiengesellschaft FI6,704,067$8.92M0.1%+0.0%4.463%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Navidea Biopharmaceuticals logo
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Read More on Navidea Biopharmaceuticals

Today's Range

Now: $1.70
Low: $1.69
High: $1.71

50 Day Range

MA: $2.08
Low: $1.88
High: $2.33

52 Week Range

Now: $1.70
Low: $1.46
High: $5.02

Volume

475 shs

Average Volume

252,817 shs

Market Capitalization

$49.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

Who are the company insiders with the largest holdings of Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' top insider investors include:
  1. John K Jr Scott (Major Shareholder)
  2. Malcolm G Witter (Director)
  3. Malcolm G Witter (Director)
  4. Jed Latkin (CEO)
America Needs This Company
This stock might just be one of America's No.1 tech investments this year.
Read more.